From fragmented work to structured systems

For most labs, the barrier to offering pharmacogenomics isn’t the science — it’s everything around it: reconciling evidence, building report software, and keeping guidance current. A white-label platform removes that overhead so a lab can launch a branded PGx service in days.

SignalPGx turns your genotyping output into finished clinical reports. Your lab runs the test and sends results, and the platform handles interpretation, medical-director review, branding, and delivery into the EHR.

Rethinking how decisions are made

The hard part of PGx isn’t calling a genotype — it’s deciding what it means for a medication, defensibly, every single time.

SignalPGx grades every gene–drug pair against trusted authorities:

• CPIC dosing guidance

• FDA pharmacogenomic labeling

• DailyMed and DPWG

Reconciled into one evidence-graded recommendation, so every result is consistent and clinician-ready.

From steps to continuous flows

PGx work is often split across disconnected tools — genotype files here, guideline PDFs there, reports built by hand. Every handoff adds delay and risk.

SignalPGx connects intake, interpretation, medical-director review, and delivery into one workflow. Results move automatically, and every report is signed out before release.

Adapting to real-world complexity

Guidelines and medication lists change. A report built once and forgotten quietly goes stale.

Living Reports re-analyze a patient’s results when guidelines or medications change, flagging anything that needs a fresh medical-director review — so guidance stays current after release.

Scaling without proportional complexity

Traditionally, scaling a PGx service means more analysts, more manual review, and more overhead.

With SignalPGx, scaling shifts to platform capacity.

Interpretation is automated, review is structured, and reports stay consistent as volume grows — so a lab can add PGx reporting with the team it already has.

decision = model.predict(input_data)
execute(decision)

Making operations visible

One advantage labs underestimate is visibility. When reporting runs on a platform, every case is trackable:

This creates clarity:

1. where each case is in the pipeline

2. which reports are awaiting review

3. what changed since the last guideline update

So nothing sits in a queue unseen, and release always stays under the lab’s control.

Conclusion

Offering pharmacogenomics doesn’t require building a software team — it requires the right platform.

Labs that white-label an evidence-graded reporting service launch faster, keep guidance current, and deliver reports their clinicians trust — under their own brand, in days rather than quarters.